Events

COST Belgian Info Day 2025
MAY
Wed
07
10:00 - 15:00

This was 11 months ago

Location

WTC III

BOSA
Room Tahiti (2nd floor)
Simon Bolivarlaan 30
1000 Brussels
Programmes
COST

The Belgian COST Contact Points will organise a COST Info Day on 7 May 2025 (10:00-15:00) in WTC III (Simon Bolivarlaan 30, 1000 Brussels). The info day will consist of two sessions:

  • general session in which COST and its networking opportunities will be presented.
  • specialised session for Belgian researchers and innovators that are preparing a COST proposal as the 'main proposer' or ‘secondary proposer’. The deadline of the next COST Open Call is 21 October 2025 at 12.00 (noon) CEST. More information here.

More information on the agenda and registration can be found here. Please register by 30 April 2025.

For questions related to this event and the COST Programme, please contact cost@fwo.be.

 

myOverview - sign up for personalised information

We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).

Stay informed about what matters to you. By signing up, you can opt in for e-mail notifications and get access to a personalised dashboard that groups all news updates and event announcements in your domain(s).

Only for stakeholders located in Flanders

Event calendar

 

Testimonial

BEAT-AF - Ground-Breaking Electroporation-based intervention for Atrial Fibrillation treatment

The Horizon2020 project BEAT-AF brings together 9 European renowned clinical centres in France, Belgium, Czechia, Germany and Austria. Together, the consortium strives to revolutionize Atrial Fibrillation (AF) treatment through catheter ablation and contribute to decrease the huge burden of AF in Europe. The BEAT-AF project kicked off in 2021 and will run until 2026. The department of electrophysiology of the AZ Sint-Jan Hospital in Bruges is partner in the project and has so far contributed to the pre-clinical development, the first in man studies and first registries of the revolutionary AF treatment put forward by the consortium. The first pilot studies show that the treatment is safe, effective and efficient.